Generated by AI
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer. Candel Therapeutics concentrates on off-the-shelf, multimodal biological therapies designed to stimulate anti-tumor immune responses and address solid tumors. Its current pipeline includes CAN-2409, an adenovirus-based program being evaluated in cancers such as prostate, non-small cell lung, and pancreatic cancer, as well as CAN-3110, a herpes simplex virus-based candidate for recurrent high-grade glioma. The company also develops the enLIGHTEN Discovery Platform, which is used to identify and advance new viral immunotherapy candidates. Headquartered in Needham, Massachusetts, Candel Therapeutics plays a specialized role in oncology by combining viral engineering with immunology to support the development of targeted cancer treatments.
Website117 Kendrick Street
Needham, MA, 02494
United States
The latest articles about CADL.
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 13's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about CADL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.